Faron Pharmaceuticals: Research program progressing as planned
We have updated our assessment of the progress of Faron’s research program and based on that, the commercial potential of the company's drug candidates. The individual studies of the research program have largely progressed as we expected and the changes to our model are moderate in size. The most important change is the increased number of blood cancer patients who could potentially benefit from bexmarilimab (BEX). However, since October, the share price has increased more than our fair value, which weakens the share’s risk/return ratio. We believe the share is close to the upper limit of its fair value range.
Login required
This content is only available for logged in users
Faron Pharmaceuticals
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Read more on company pageKey Estimate Figures09.01.2023
| 2021 | 22e | 23e | |
|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 |
| growth-% | |||
| EBIT (adj.) | -21.1 | -22.1 | -0.8 |
| EBIT-% (adj.) | -527,700.00 % | -551,975.00 % | -20,292.50 % |
| EPS (adj.) | -0.40 | -0.37 | -0.02 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | - | - | - |
| EV/EBITDA | - | - | - |
